Oncologist Specializing in Sarcomas Joins Isabella Santos Solid & Rare Tumor Program at Levine Children’s
Oncologist Specializing in Sarcomas Joins Isabella Santos Solid & Rare Tumor Program at Levine Children’s
Your donations at work! This summer we introduced you to Dr. Giselle Sholler, the new director for the Isabella Santos Foundation Rare & Solid Tumor Program at Levine Children’s. Ever since her arrival, this program has taken off and is growing very rapidly. Development of the program requires the need for specialized personnel to help focus on research and novel therapies. Since July 2020, the program has had more than 20 referrals, some even emerging internationally.
Due to your financial support, Atrium Health Levine Children’s successfully brought Dr. Erin Trovillion onto the Isabella Santos Foundation Rare & Solid Tumor Program Team. We are extremely excited about the expertise she brings in sarcomas. Dr. Trovillion is a New Jersey native who comes to us from University of California – San Diego, where she focused on solid tumors and sarcomas.
Dr. Trovillion will be responsible for clinical care in the outpatient setting, working closely with Dr. Sholler and Dr. Oesterheld in elevating the comprehensive model of care to include medical, psychological, and integrative support. Her clinical interest will focus primarily on Osteosarcoma, Ewing’s Sarcoma, Rhabdomyosarcoma, and other solid tumors.
The Isabella Santos Foundation Rare & Solid Tumor Program will provide the most comprehensive care and treatments for pediatric cancer in our community and across the globe. This clinic will offer the most advanced clinical treatments, including precision medicine and novel clinical trials, to bring forward the newest therapies and improve outcomes in childhood cancer.
Thank you for your support in making this program a reality. We cannot tackle pediatric cancer without you. Please help us welcome Dr. Trovillion to Charlotte and to Levine Children’s. We look forward to seeing all she accomplishes for kids fighting rare cancers.